Dr. Olivier Litzka
CEO
management
Noxxon Pharma
Switzerland
Biography
Dr. Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006. He invests in European and US biotechnology and medtech companies. In addition to being a member of the supervisory board of NOXXON Pharma AG he currently serves on the board of Autonomic Technologies Inc. (Redwood City), Allecra (St Louis), JenaValve (Irvine/Munich), Medlumics (Madrid) and SuperSonic Imagine (Aix en Provence). Up until its acquisition by AstraZeneca, he was also a member of the board of Novexel (France), as well as a member of the board of Endosense (Geneva) up until the company’s acquisition by St Jude Medical and a member of the board of Sapiens Steering Brain Stimulation (Eindhoven) up until its acquisition by Medtronic. Until end of 2016, he was also member of the board of public company Probiodrug (Halle). Before joining EdRIP, Olivier Litzka spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris. Dr. Litzka holds a Ph.D. in molecular microbiology from the University of Munich.
Research Interest
molecular microbiology
